Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.73
+3.0%		$1.34
$0.87
▼
$2.99
$125.40M-0.281.49 million shs1.17 million shs
Cibus, Inc. stock logo
CBUS
Cibus
$1.65
-1.2%		$1.73
$1.09
▼
$4.19
$126.11M1.61146,230 shs89,727 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.66
-7.6%		$2.84
$2.29
▼
$8.53
$120.35M0.6388,366 shs415,357 shs
MDNAF
Medicenna Therapeutics
$0.35
+7.3%		$0.28
$0.23
▼
$1.43
$32.31M1.7849,093 shs6,857 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%+26.28%+41.80%+25.36%-6.99%
Cibus, Inc. stock logo
CBUS
Cibus
0.00%-2.94%-14.51%+14.58%+25.00%
Genelux Corporation stock logo
GNLX
Genelux
0.00%-2.21%-12.79%-12.79%-26.92%
MDNAF
Medicenna Therapeutics
0.00%+20.32%+41.70%+12.18%+34,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.73
+3.0%		$1.34
$0.87
▼
$2.99
$125.40M-0.281.49 million shs1.17 million shs
Cibus, Inc. stock logo
CBUS
Cibus
$1.65
-1.2%		$1.73
$1.09
▼
$4.19
$126.11M1.61146,230 shs89,727 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.66
-7.6%		$2.84
$2.29
▼
$8.53
$120.35M0.6388,366 shs415,357 shs
MDNAF
Medicenna Therapeutics
$0.35
+7.3%		$0.28
$0.23
▼
$1.43
$32.31M1.7849,093 shs6,857 shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%+26.28%+41.80%+25.36%-6.99%
Cibus, Inc. stock logo
CBUS
Cibus
0.00%-2.94%-14.51%+14.58%+25.00%
Genelux Corporation stock logo
GNLX
Genelux
0.00%-2.21%-12.79%-12.79%-26.92%
MDNAF
Medicenna Therapeutics
0.00%+20.32%+41.70%+12.18%+34,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.67
Moderate Buy$9.00420.23% Upside
Cibus, Inc. stock logo
CBUS
Cibus
2.00
Hold$9.00445.45% Upside
Genelux Corporation stock logo
GNLX
Genelux
2.50
Moderate Buy$18.00576.69% Upside
MDNAF
Medicenna Therapeutics
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest MDNAF, CBUS, BMEA, and GNLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/18/2026
Genelux Corporation stock logo
GNLX
Genelux
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy
7/17/2026
Genelux Corporation stock logo
GNLX
Genelux
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/1/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/29/2026
Cibus, Inc. stock logo
CBUS
Cibus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/16/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/12/2026
Cibus, Inc. stock logo
CBUS
Cibus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$0.17 per shareN/A
Cibus, Inc. stock logo
CBUS
Cibus
$4.35M29.01N/AN/A$0.19 per share8.68
Genelux Corporation stock logo
GNLX
Genelux
$10K12,033.84N/AN/A$0.36 per share7.39
MDNAF
Medicenna Therapeutics
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$61.80M-$0.29N/AN/AN/AN/A-253.73%-97.91%11/3/2026 (Estimated)
Cibus, Inc. stock logo
CBUS
Cibus
-$127.08M-$1.65N/AN/AN/A-2,258.89%-287.03%-27.99%11/12/2026 (Estimated)
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-205.85%-138.79%11/4/2026 (Estimated)
MDNAF
Medicenna Therapeutics
-$13.32M-$0.16N/AN/AN/AN/A-1.04%-0.49%N/A

Latest MDNAF, CBUS, BMEA, and GNLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Cibus, Inc. stock logo
CBUS
Cibus
-$0.19-$0.29-$0.10-$0.29$1.70 million$0.99 million
8/13/2026Q2 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1967-$0.21-$0.0133-$0.21N/AN/A
8/6/2026Q2 2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.2235-$0.12+$0.1035-$0.12N/AN/A
6/25/2026Q4 2026
MDNAF
Medicenna Therapeutics
-$0.05-$0.05N/A-$0.06N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Cibus, Inc. stock logo
CBUS
Cibus
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
MDNAF
Medicenna Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
3.47
3.47
Cibus, Inc. stock logo
CBUS
Cibus
N/A
1.62
1.62
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39
MDNAF
Medicenna Therapeutics
N/A
1.52
1.52

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Cibus, Inc. stock logo
CBUS
Cibus
33.81%
Genelux Corporation stock logo
GNLX
Genelux
37.33%
MDNAF
Medicenna Therapeutics
35.85%

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
10.60%
Cibus, Inc. stock logo
CBUS
Cibus
29.91%
Genelux Corporation stock logo
GNLX
Genelux
7.50%
MDNAF
Medicenna Therapeutics
33.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5072.48 million64.80 millionOptionable
Cibus, Inc. stock logo
CBUS
Cibus
4876.43 million53.57 millionOptionable
Genelux Corporation stock logo
GNLX
Genelux
1045.24 million41.85 millionNot Optionable
MDNAF
Medicenna Therapeutics
2092.30 million61.75 millionN/A

Recent News About These Companies

FY2027 EPS Estimates for OTCMKTS:MDNAF Boosted by Analyst
August 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30979237
HC Wainwright Comments on OTCMKTS:MDNAF Q1 Earnings
August 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30977465
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345226/0/en/medicenna-therapeutics-reports-first-quarter-fiscal-2027-financial-results-and-announces-oral-presentations-at-upcoming-conferences.html
Medicenna Therapeutics Corp. GAAP EPS of -C$0.22
June 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4607730-medicenna-therapeutics-corp-gaap-eps-of-c022?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=news?source=MarketBeat
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
June 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/26/3318221/0/en/medicenna-therapeutics-reports-fiscal-year-2026-financial-results-and-operational-highlights.html
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026  |  financialpost.comF
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310335/0/en/medicenna-strengthens-u-s-patent-estate-with-newly-issued-and-allowed-patents-across-its-il-2-il-4-and-il-13-superkine-platforms.html
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3305914/0/en/medicenna-s-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026.html
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
May 28, 2026  |  financialpost.comF
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
May 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/28/3302952/0/en/medicenna-announces-closing-of-public-offering-of-units-raising-cdn-4-44-million-to-support-lead-programs.html
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
May 22, 2026  |  financialpost.comF
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300037/0/en/medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet.html
Medicenna Announces the Launch of a Marketed Public Offering of Securities
May 13, 2026  |  financialpost.comF
Medicenna Announces the Launch of a Marketed Public Offering of Securities
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294403/0/en/medicenna-announces-the-launch-of-a-marketed-public-offering-of-securities.html
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292647/0/en/medicenna-and-fondazione-melanoma-onlus-announce-first-patient-dosed-in-the-neo-cyt-study-of-mdna11-in-neoadjuvant-melanoma.html
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284740/0/en/medicenna-and-fondazione-melanoma-onlus-announce-presentation-on-neocyt-trial-at-asco-2026.html
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2026  |  financialpost.comF
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273234/0/en/medicenna-to-present-at-the-2026-bloom-burton-co-healthcare-investor-conference.html
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
April 9, 2026  |  financialpost.comF
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
March 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/18/3258064/0/en/medicenna-to-present-preclinical-data-from-its-first-in-class-tumor-anchored-and-conditionally-activated-anti-pd-1-il-2-bifunctional-superkine-at-the-aacr-annual-meeting-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.73 +0.05 (+2.98%)
As of 08/28/2026 04:00 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Cibus stock logo

Cibus NASDAQ:CBUS

$1.65 -0.02 (-1.20%)
As of 08/28/2026 04:00 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Genelux stock logo

Genelux NASDAQ:GNLX

$2.66 -0.22 (-7.64%)
As of 08/28/2026 04:00 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Medicenna Therapeutics OTCMKTS:MDNAF

$0.35 +0.02 (+7.26%)
As of 08/28/2026 12:57 PM Eastern

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas